ARA-290 (cibinetide) is a synthetic 11-amino acid peptide corresponding to the helix-B surface domain of erythropoietin (EPO). It is a non-erythropoietic peptide, meaning it does not stimulate red blood cell production, and is a frequent subject of laboratory research. It is supplied as a lyophilized powder for research use only.
In published in vitro and preclinical research, ARA-290 has been studied in connection with selective binding to the innate repair receptor (IRR) — a heterocomplex of the EPO receptor and the beta-common receptor (CD131) — without engaging the classical erythropoietic pathway. These studies are conducted in cell-culture and animal research models. The findings derive from laboratory research and do not describe or imply any effect, benefit, or use in humans or animals.
Published literature has examined ARA-290 across a range of cell-culture and animal research models relating to IRR/CD131 receptor signaling biology. These reports reflect controlled laboratory conditions only and do not translate to dosing, treatment, or applications in any other context.
For further reading, see published research on ARA-290 / cibinetide on PubMed.
Product Specifications
| CAS Number | 1208243-50-8 |
| PubChem CID | 91810664 |
| Molecular Formula | C₅₁H₈₄N₁₆O₂₁ |
| Molecular Weight | ~1,257.3 g/mol |
| Amino Acid Count | 11 |
| Sequence | XEQLERALNSS |
| Synonyms | Cibinetide, PHBSP |
| Purity | ≥99% by HPLC | COA available |
| Physical Form | Lyophilized powder |
| Storage Conditions | Store at −20°C; protect from light and moisture |
For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures. This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. Not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.
Reviews
There are no reviews yet.